Eli Lilly and Company (LLY)

NYQ – Real vaqt narxi. Valyuta: USD

1182.62

+3.35 (0.28%)

Yopilishda: Oct 12, 2026, 4:00 PM EDT

1195.00

+12.38 (1.05%)

Bozor oldidan: Oct 13, 2026, 5:34 AM EDT

13.10.2026

Will Eli Lilly Do a Stock Split Before the End of 2026?

Stock splits are discretionary and aren't a guarantee, even if the stock price soars well over $1,000. Eli Lilly has not done a stock split in nearly 30 years.

12.10.2026

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

AbbVie continues to diversify its portfolio through the successful expansion of newer therapies like Skyrizi and Rinvoq. Eli Lilly and has seen explosive growth driven by its dominant presence in the massive cardiometabolic treatment market.

12.10.2026

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

NVO's 11% slide in a month reflects intensifying LLY competition, pricing pressure and a lack of near-term growth visibility despite its long-term pipeline potential.

12.10.2026

This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock

Eli Lilly recently announced results from a clinical trial that showed the company may have an even better weight loss treatment in the works. Patients who took tirzepatide along with eloralintide were able to lose as much as 23.3% of their weight after 48 weeks.

12.10.2026

Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.

The best explanation of Lilly's recent 8% pullback is probably that investors are profit-taking. Lilly's growth story remains strong with impressive demand for its GLP-1 drugs.

11.10.2026

Top 50 High-Quality Dividend Growth Stocks For October 2026

I track an investable universe of 50 high-quality dividend growth stocks to identify attractive entry points based on valuation and future return potential. Applied Materials, D.R. Horton, and Home Depot saw notable ranking improvements due to upgraded EPS growth estimates and/or favorable valuation shifts. 44 out of 50 stocks currently offer a forward return estimate of at least 10%, with 32 appearing potentially undervalued based on free cash flow mean reversion.

09.10.2026

Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock

Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Videolar

22.09.2026

Positive

Ken Langone on Eli Lilly: Could be a $2,000 stock in the next 3-4 years

18.09.2026

Positive

40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"

15.09.2026

Neutral

Tuesday's First Moves: LLY & ETSY Upgrades, PLAY Plunges After Earnings

15.09.2026

Positive

Options Corner: LLY Upgrade Injects Bullish Stock Momentum

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
LLY	Berenberg	Buy	undefined >> $1,400	September 15th 2026

Press-relizlar

09.10.2026

New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) advance understanding of the interconnected immune and metabolic biology in adults with psoriasis and obesity

Exploratory data presented at Fall Clinical 2026 showed broader biomarker changes with Taltz and Zepbound vs. Taltz alone as early as Week 12 in first-of-its-kind TOGETHER-PsO study INDIANAPOLIS, Oct. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared with Taltz alone in adults with moderate-to-severe plaque psoriasis and obesity or overweight with at least one additional weight-related comorbid condition.

02.10.2026

Lilly's Jaypirca (pirtobrutinib), the first-and-only approved non-covalent BTK inhibitor, receives expanded indication from U.S. FDA for certain patients with previously untreated CLL/SLL

INDIANAPOLIS, Oct. 2, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved an additional indication for Jaypirca (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, for the treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) with no known 17p deletion. This approval allows for the use of Jaypirca as a first-line treatment for appropriate patients.

01.10.2026

Lilly's oral GLP-1, Foundayo (orforglipron), was associated with significant reductions in predicted long-term risk of type 2 diabetes and cardiovascular disease

In post-hoc analyses of ATTAIN-1, Foundayo 17.2 mg was associated with a predicted 57% and 18% reduction in risk of type 2 diabetes and cardiovascular disease vs. placebo Combined with recent research on the savings tied to weight loss, these findings suggest Foundayo could help reduce long-term spending for patients and healthcare systems INDIANAPOLIS, Oct. 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), today announced results from post-hoc analyses of ATTAIN-1 showing that Foundayo was associated with significant reductions in predicted 10-year risk of type 2 diabetes and cardiovascular disease in adults with obesity or overweight with a weight-related medical problem.

30.09.2026

Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study

In ACHIEVE-4, participants taking Foundayo experienced a 16% lower risk of MACE-4 and a 23% lower risk of MACE-3, meeting the primary objective for non-inferiority compared to insulin glargine In pre-planned analyses, Foundayo showed a 53% lower risk of cardiovascular death and a 57% lower risk of all-cause death vs. insulin glargine, suggesting the potential for more comprehensive health benefits INDIANAPOLIS, Sept.

Eli Lilly and Company (LLY)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Biz bilan bog'lanish

Bizni kuzating

Eli Lilly and Company (LLY)

Will Eli Lilly Do a Stock Split Before the End of 2026?

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Novo Down 11% in a Month: How Should Investors Approach the Stock Now?

This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock

Eli Lilly Stock Has Pulled Back 8%. History Says This Is What Happens Next.

Top 50 High-Quality Dividend Growth Stocks For October 2026